5 Analysts Have This to Say About Sutro Biopharma
Portfolio Pulse from Benzinga Insights
Sutro Biopharma (NASDAQ:STRO) has received 5 analyst ratings in the last quarter, with 2 being bullish and 3 somewhat bullish. The average price target is $16.0, representing a significant upside from the current price of $3.59. However, this average represents a 20.0% decrease from the previous average price target of $20.00.
October 06, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sutro Biopharma has received positive analyst ratings, which could potentially drive the stock price up in the short term.
Analyst ratings often influence investor sentiment and can drive stock prices. In this case, Sutro Biopharma has received mostly positive ratings, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100